Fangzhou (HKEX: 06086) has announced the appointment of Wang Haijiao as chief executive officer (CEO) and executive director, effective today.
Mr. Wang’s nearly 20 years of extensive healthcare industry experience in entrepreneurship, management, and investment is complemented by deep expertise in digital health, precision medicine, and in vitro diagnostics. Prior to joining Fangzhou, Mr. Wang served as the deputy general manager, investment committee member, and executive partner of GTJA Investment Group, which he joined in 2014.
In a statement, Mr. Wang commented, “I am highly honored to join Fangzhou Inc. at such a transformative period in its history. The company has built an unparalleled digital healthcare infrastructure and recently achieved a remarkable financial turnaround. I look forward to working with the Board and our talented team to deepen our ‘AI + CDM’ strategy, leveraging our proprietary XS LLM to empower our network of over 250,000 physicians and improve the standard of care for our millions of patients. Together, we will continue to drive innovation and sustainable growth.”
Feng Zhou, CSO and executive director of Fangzhou, remarked, “The Board is delighted to welcome Mr. Wang as our new CEO. His deep understanding of the healthcare ecosystem, proven track record in digital health investments, and robust leadership skills make him the ideal executive to guide Fangzhou into its next phase of growth. We are confident that under his leadership, the company will continue to successfully execute its ‘Medicine as a Service’ (MaaS) and ‘AI + CDM’ strategies.”
